MYC and neoplasm: Tumor volumes were measured every 2–3 days post-injection, and the results showed that trametinib significantly inhibited tumor growth, reducing the tumor size by 30% in JHU22-LV tumors and by 50.2% in JHU22-MYC tumors compared to their respective vehicle-treated controls at the study endpoint.